sanofi
Rona’s Sanofi-Sourced siRNA Demonstrates Early Efficacy in Dyslipidaemia Treatment
siRNA, dyslipidaemia, Rona, Sanofi, RNA interference, lipid disorders, therapeutic development
Dupixent (Dupilumab) Advances Towards FDA Approval for Chronic Spontaneous Urticaria (CSU) in 2025
Dupixent, Dupilumab, Chronic Spontaneous Urticaria (CSU), FDA Review, Sanofi, Regeneron, Biologic Medicine, Type 2 Inflammation, H1 Antihistamines
Sanofi’s Rilzabrutinib Shows Promising Results in Phase III Trial for Immune Thrombocytopenia (ITP)
Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study
Sanofi Invests €300M in Orano Med for Next-Generation Radioligand Therapies
Sanofi, Orano Med, Radioligand Therapies, Rare Cancers, AlphaMedix, Lead-212 (212Pb), Targeted Alpha Therapies
Sanofi Workers Strike Over Consumer Health Unit Sale Amid Job Loss and Strategic Asset Concerns
Sanofi, strike, consumer health unit, sale, job losses, strategic assets, France, Doliprane, Opella, Clayton Dubilier & Rice
Sanofi’s Frexalimab Shows Promise in Multiple Sclerosis with Positive Phase 2 Results
Sanofi, Frexalimab, Multiple Sclerosis, Phase 2 Trial, CD40L Antibody
GSK, Sanofi, and CSL Secure $72 Million BARDA Funding to Enhance Bird Flu Vaccine Supply
BARDA funding, bird flu vaccine, GSK, Sanofi, CSL, vaccine supply, public health
Recordati Acquires Sanofi’s Rare Disease Drug Enjaymo in $825M Deal
Recordati, Sanofi, Enjaymo, rare disease, cold agglutinin disease (CAD), pharmaceutical acquisition
Sanofi and Regeneron’s Dupixent Secures Historic FDA Approval as First Biologic Treatment for COPD
Dupixent, COPD, FDA Approval, Biologic Treatment, Sanofi, Regeneron
Sanofi Receives Bids from Private Equity Firms for $16B+ Consumer Health Business
Sanofi, private equity firms, consumer health business, PAI Partners, Clayton, Dubilier & Rice, Bloomberg